Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 3/20 | 0.39 |
| ▸ | CES1 | P23141 | 3/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nonane SCHEMBL8960871 | 1.00 | TSHR (0.50) | TSHRALDH1A1THRBLMNAEPHX1 | |
| Octane SCHEMBL4626385 | 1.00 | TSHR (0.50) | TSHRALDH1A1THRBLMNAEPHX1 | |
| Heptane SCHEMBL25303431 | 0.97 | ALDH1A1 (0.47) | TSHRALDH1A1THRBLMNAEPHX1 | |
| Heptane SCHEMBL4434566 | 0.97 | ALDH1A1 (0.47) | TSHRALDH1A1THRBLMNAEPHX1 | |
| Hexane SCHEMBL5237862 | 0.97 | ALDH1A1 (0.53) | TSHRALDH1A1THRBLMNAEPHX1 | |
| Hexane SCHEMBL22134480 | 0.97 | ALDH1A1 (0.53) | TSHRALDH1A1THRBLMNAEPHX1 | |
| Hexane SCHEMBL224276 | 0.97 | ALDH1A1 (0.53) | TSHRALDH1A1THRBLMNAEPHX1 | |
| Hexane SCHEMBL14895621 | 0.97 | ALDH1A1 (0.53) | TSHRALDH1A1THRBLMNAEPHX1 | |
| Nonane SCHEMBL9452411 | 0.94 | TSHR (0.44) | TSHRALDH1A1THRBLMNACES2 | |
| Heptane SCHEMBL21580605 | 0.94 | TSHR (0.44) | TSHRALDH1A1THRBLMNACES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118271264-A | Method for continuously extracting and separating tetrahydrofuran and methanol mixed solvent | 山东汇海医药化工有限公司 | 2024-07-02 | — | — | CN | claimed |
| CN-117945936-A | Method for preparing 5-aminolevulinic acid hydrochloride | 江苏联环药业股份有限公司 | 2024-04-30 | — | — | CN | claimed |
| US-20220023268-A1 | CRYSTALLINE FORMS OF 3-[5-(2-FLUOROPHENYL)-[1,2,4]OXADIAZOL-3-YL]-BENZOIC ACID FOR THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. | 2022-01-27 | — | — | US | claimed |
| CN-108794342-A | Ammonium carboxylate salt compound, its crystal form, amorphous substance and preparation method thereof | 武汉朗来科技发展有限公司 | 2018-11-13 | — | — | CN | claimed |
| US-8748625-B2 | Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid | PTC THERAPEUTICS, INC. (US) | 2014-06-10 | — | — | US | claimed |
| US-20130158081-A1 | CRYSTALLINE FORMS OF 3-[5-(2-FLUOROPHENYL)-[1,2,4]OXADIAZOL-3-YL]-BENZOIC ACID | PTC THERAPEUTICS, INC. (US) | 2013-06-20 | — | — | US | claimed |
| EP-2559689-A1 | Preparation process for crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]benzoic acid | PTC Therapeutics, Inc. (US) | 2013-02-20 | — | — | EP | claimed |
| CN-100497285-C | Method for synthesizing inverse-4-(inverse-4'-alkyl cyclohexyl) cyclohexyl methyl aldehyde | XI AN RUILIAN MODERN ELECTRONI (CN) | 2009-06-10 | — | — | CN | claimed |
| CN-101062889-A | Method for synthesizing inverse-4-(inverse-4'-alkyl cyclohexyl) cyclohexyl methyl aldehyde | XI AN RUILIAN MODERN ELECTRONI (CN) | 2007-10-31 | — | — | CN | claimed |
| EP-0915898-B1 | CRYSTAL FORM I OF CLARITHROMYCIN | ABBOTT LAB (US) | 2003-12-03 | — | — | EP | claimed |
| WO-2003002548-A1 | A PROCESS FOR THE PREPARATION OF CHIRAL GLUCOCORTICOID RECEPTOR AGENTS | ABBOTT LABORATORIES (US) | 2003-01-09 | — | — | WO | claimed |
| EP-0915898-A1 | CRYSTAL FORM I OF CLARITHROMYCIN | Abbott Laboratories (US) | 1999-05-19 | — | — | EP | claimed |
| US-5858986-A | CONVERTING ERYTHROMYCIN A INTO ITS 9-OXIME DERIVATIVE; PROTECTING 2' AND 4? HYDROXY GROUPS; METHYLATION; DEPROTECTING AND DEOXIMATING; TREATING WITH SOLVENT; ISOLATION; DRYING | ABBOTT LABORATORIES (US) | 1999-01-12 | — | — | US | claimed |
| WO-1998004573-A1 | CRYSTAL FORM I OF CLARITHROMYCIN | ABBOTT LABORATORIES (US) | 1998-02-05 | — | — | WO | claimed |
| EP-4392423-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | Arthrosi Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| CN-118271264-A | Method for continuously extracting and separating tetrahydrofuran and methanol mixed solvent | 山东汇海医药化工有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118271264-A | Method for continuously extracting and separating tetrahydrofuran and methanol mixed solvent | 山东汇海医药化工有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-4163853-A | 1-(P-phenoxy)benzyl-1,2,3,4,5,6,7,8-octahydroisoquinolines | HOFFMANN-LA ROCHE INC. (US) | 1979-08-07 | — | — | US | disclosed |
| US-4113729-A | ANALGESICS, NARCOTIC ANTAGONISTS | HOFFMANN-LA ROCHE INC. (US) | 1978-09-12 | — | — | US | disclosed |
| US-4011147-A | METHOD FOR DIAPHRAGM ELECTROLYSIS OF ALKALI METAL HALIDES | MARUZEN OIL CO. LTD. (JA) | 1977-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158081-A1 | CRYSTALLINE FORMS OF 3-[5-(2-FLUOROPHENYL)-[1,2,4]OXADIAZOL-3-YL]-BENZOIC ACID | UPF1, RNMT, EIF4A2 | TSHR 2920/4885ALDH1A1 3399/4885THRB 3956/4885 |
| US-20220023268-A1 | CRYSTALLINE FORMS OF 3-[5-(2-FLUOROPHENYL)-[1,2,4]OXADIAZOL-3-YL]-BENZOIC ACID FOR THE TREATMENT OF DISEASE | UPF1, RNMT, RBM17 | TSHR 2894/4885ALDH1A1 3498/4885THRB 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.